首页|期刊导航|南京医科大学学报(自然科学版)|实体瘤软脑膜转移的诊断与鞘内治疗现状

实体瘤软脑膜转移的诊断与鞘内治疗现状OA

Leptomeningeal metastases from solid tumors:current status of diagnosis and intrathecal treatment

中文摘要英文摘要

软脑膜转移(leptomeningeal metastasis,LM)是实体瘤中虽罕见但预后极差的严重并发症,常见于肺癌、乳腺癌及恶性黑色素瘤患者,发生率为1%~5%.LM具有诊断难度高、病程进展快及缺乏统一治疗规范等特点.鞘内给药作为重要治疗策略,可将药物直接输送至蛛网膜下腔,从而显著提高局部药物浓度.传统鞘内化疗药物主要有甲氨蝶呤、阿糖胞苷及塞替哌;近年来,随着药物研发的持续推进,多种新型化疗药物、靶向治疗药物以及免疫检查点抑制剂逐步应用于鞘内治疗.与此同时,对LM发病机制的深入研究,以及脑脊液循环肿瘤细胞和循环肿瘤DNA等先进检测技术的发展,为LM的早期诊断与个体化治疗带来新的机遇.文章系统综述LM的诊断方法及鞘内治疗研究进展.

Leptomeningeal metastasis(LM)is a rare yet devastating complication of solid tumors,frequently occurring in patients with lung cancer,breast cancer,or malignant melanoma,with an incidence of approximately 1%-5%.Diagnosis remains difficult,prognosis is poor,and no standardized treatment currently exists.Intrathecal administration,as a therapeutic approach,enables the direct delivery of drugs into the subarachnoid space,thereby increasing local drug concentrations.Conventional intrathecal chemotherapeutic agents primarily include methotrexate,cytarabine,and thiotepa.In recent years,with advances in drug development,a variety of novel chemotherapeutics,targeted agents,and immune checkpoint inhibitors have gradually been introduced into intrathecal therapy.Furthermore,in-depth investigation into the pathogenesis of LM,along with the development of diagnostic techniques such as detection of circulating tumor cells and circulating tumor DNA in cerebrospinal fluid is offering new opportunities for LM diagnosis and therapeutic strategies.This review provides a comprehensive summary of the current diagnostic approaches and research progress in intrathecal treatment for LM.

查梦瑶;曹楷;李薇

南京医科大学第一附属医院乳腺中心,江苏 南京 210029南京医科大学第一附属医院乳腺中心,江苏 南京 210029南京医科大学第一附属医院乳腺中心,江苏 南京 210029

医药卫生

软脑膜转移鞘内治疗诊断

leptomeningeal metastasisintrathecal therapydiagnosis

《南京医科大学学报(自然科学版)》 2026 (5)

751-761,11

国家自然科学基金(81772475)青岛市科技计划园区培育计划项目(25-1-1-yqpy-6-qy)

10.7655/NYDXBNSN250992

评论